Loading
A phase 1/2 trial of IMA402 in advanced solid tumours, run by Immatics Biotechnologies GmbH, now recruiting.
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT05958121 by Immatics Biotechnologies GmbH, with 400 participants planned, started 2023-08-09 and due to reach its primary completion in 2027-09. Interventions recorded: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody and IMA402 and chemotherapy +/- monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Immatics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/